In recognition of World Alzheimer’s month, I’m honored to reach out to each of you to thank you for your efforts to impact dementia as each of you play a role at C-Path in supporting our consortium.
CAMD’s successes including globally accepted consensus data standards, our CAMD database consisting of data from worldwide Alzheimer’s clinical trials and our regulatory decisions by EMA and FDA collectively serve as true examples to the coalition’s dedication to making a difference throughout the world.
As a testimony to our global impact, we are excited to announce that Alzheimer’s Research UK has joined as our newest member of CAMD.
“Alzheimer’s Research UK is proud to join the Coalition Against Major Diseases and contribute to accelerating the development of new treatments for neurodegeneration. As one of the world’s leading dementia research charities, our mission is to speed up the translation of promising scientific ideas into real world benefits for people with dementia. As well as supporting leading researchers in the UK, we fund the best scientific teams around the world, working in collaboration with other funders to bring greater combined efforts to bear on one of our greatest medical challenges. Over 44 million people are living with dementia across the world, and coalitions like CAMD are crucial routes to bringing innovative funders, regulators, universities and Pharma together to find breakthroughs in disease treatment and prevention.”
We are thrilled to welcome Alzheimer’s Research UK as our newest member to join us in our quest to continue to make impact in accelerating treatments for the millions around the world in desperate need. Dr. Eric Karran, Director of Research Strategy at Alzheimer’s Research UK has kindly agreed to participate in our CAMD annual meeting taking place next month (Oct 20th) at FDA.
Diane Stephenson, PhD
Executive Director, Coalition Against Major Diseases